Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (385)	9/22/1999 12:09:00 PM
From: Biomaven	Respond to of 52153

An interesting recent phenomenon: Used to be the announcement of a secondary produced considerable short-term weakness. But take a look at PCYC recently, and VPHM and IMCL today. (BTW, I'm still wondering what's happened to the PCYC offering - it was announced a long time ago and a lot of points lower. Could it be that there is something in the works that has delayed things and caused the price to surge?) Peter

To: Biomaven who wrote (385)	9/29/1999 7:26:00 AM
From: Jim Oravetz	Respond to of 52153

<ENMD is due to enter the clinic shortly> Shrinking tumors. Despite its notoriety, however, endostatin isn't the first drug of its kind to be tried on human cancer patients. A similar drug, known as combrestatin, is well along in the initial phase of human testing. Both are so-called antiangiogenesis drugs, which are aimed at choking off the growth of blood vessels around a tumor, causing it to shrink. But unlike endostatin, which stops the growth of new blood vessels around the tumor, combrestatin attacks the lining of vessels that grow around tumors, shutting them down. For nine months, U.S. News followed the trials of two combrestatin volunteers to see how a test is conducted. Their experiences–one hopeful and one heartbreaking–offer a glimpse of what the endostatin trials might hold…..snip usnews.com Jim